Ultragenyx Pharmaceu (RARE)

$24.01 -0.10 (-0.41%)
Market Cap 2.35B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 719,819
Avg Vol 2,439,302
Day's Range N/A - N/A
Shares Out 96.48M
Stochastic %K 69%
Beta 0.15
Analysts Strong Sell
Price Target $67.35

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
roaringcharts
roaringcharts Jan. 14 at 3:24 PM
$VXX $ROLR $RARE High Roller Technologies Partners with Crypto.com to Enter the Rapidly Growing Prediction Markets Space The binding strategic partnership agreement with Crypto.com to power event-based Prediction Markets, with a Mature Market Estimated to exceed $1.X Trillion in annual trading volume1 Las Vegas, Nevada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. (“High Roller”) (NYSE: ROLR), operator of the award-winning, premium online casino brands High Roller and Fruta, today announced it has entered into a binding Letter of Intent (the “LOI”) with Crypto.com | Derivatives North America (“CDNA”), for an exclusive partnership to launch an event-based prediction markets product in the United States of America.
0 · Reply
roaringcharts
roaringcharts Jan. 14 at 12:24 AM
$RARE Still in watch https://x.com/i/status/2010693911732187382
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 2:40 PM
$RARE $EVTV $SPRC REAL COMPANY REAL REVS APPROVED DRUGS CASH ON HAND Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome
0 · Reply
NoOriginality
NoOriginality Jan. 13 at 1:14 PM
$BCTX Eyes are still on $RARE for January biotech gains.
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 12:43 PM
$RARE steady climb
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 10:38 AM
$RARE they're buying SG Americas Securities LLC established a new position in Ultragenyx by purchasing 125,429 shares in Q3, worth about $3.77 million and representing roughly 0.13% of the company.
0 · Reply
OptionRunners
OptionRunners Jan. 12 at 7:52 PM
$RARE bull risk reversals
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 7:19 PM
$RARE 3 quarters of a billion is cash is insane 4 approved rev stream Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 7:16 PM
$RARE all is well
0 · Reply
Zero11
Zero11 Jan. 12 at 6:38 PM
$RARE $MREO upppp
2 · Reply
Latest News on RARE
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:55 PM EST - 1 day ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 2 days ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 14 days ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 14 days ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Dec 30, 2025, 9:52 AM EST - 15 days ago

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 16 days ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 16 days ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 16 days ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2025, 4:30 PM EST - 25 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 4 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ABBV ALGT CGNX COHR EOLS INSP LTH

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:23 PM EST - 5 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 3:13 AM EST - 6 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 12:26 AM EST - 2 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 2 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 2 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 3 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 10:13 AM EDT - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:17 PM EDT - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 4 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 2:27 PM EDT - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 4 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 5 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:42 AM EDT - 5 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 6 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Jul 29, 2025, 9:10 AM EDT - 6 months ago

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

Jul 28, 2025, 1:16 PM EDT - 6 months ago

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Jul 18, 2025, 3:07 PM EDT - 6 months ago

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 14, 2025, 8:14 AM EDT - 6 months ago

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AAPL

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Jul 11, 2025, 4:45 PM EDT - 6 months ago

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Jul 11, 2025, 4:30 PM EDT - 6 months ago

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Jul 10, 2025, 10:06 AM EDT - 6 months ago

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jul 10, 2025, 8:00 AM EDT - 6 months ago

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MEI

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Jul 9, 2025, 4:05 PM EDT - 6 months ago

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Jun 27, 2025, 8:00 AM EDT - 7 months ago

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 5:00 PM EDT - 8 months ago

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

May 14, 2025, 4:30 PM EDT - 8 months ago

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

May 7, 2025, 5:00 PM EDT - 8 months ago

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:31 PM EDT - 9 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

May 6, 2025, 4:01 PM EDT - 9 months ago

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Apr 30, 2025, 5:00 PM EDT - 9 months ago

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 9 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 11 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 9:53 PM EST - 11 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Feb 13, 2025, 4:01 PM EST - 11 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Feb 6, 2025, 4:30 PM EST - 1 year ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

roaringcharts
roaringcharts Jan. 14 at 3:24 PM
$VXX $ROLR $RARE High Roller Technologies Partners with Crypto.com to Enter the Rapidly Growing Prediction Markets Space The binding strategic partnership agreement with Crypto.com to power event-based Prediction Markets, with a Mature Market Estimated to exceed $1.X Trillion in annual trading volume1 Las Vegas, Nevada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. (“High Roller”) (NYSE: ROLR), operator of the award-winning, premium online casino brands High Roller and Fruta, today announced it has entered into a binding Letter of Intent (the “LOI”) with Crypto.com | Derivatives North America (“CDNA”), for an exclusive partnership to launch an event-based prediction markets product in the United States of America.
0 · Reply
roaringcharts
roaringcharts Jan. 14 at 12:24 AM
$RARE Still in watch https://x.com/i/status/2010693911732187382
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 2:40 PM
$RARE $EVTV $SPRC REAL COMPANY REAL REVS APPROVED DRUGS CASH ON HAND Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome
0 · Reply
NoOriginality
NoOriginality Jan. 13 at 1:14 PM
$BCTX Eyes are still on $RARE for January biotech gains.
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 12:43 PM
$RARE steady climb
0 · Reply
roaringcharts
roaringcharts Jan. 13 at 10:38 AM
$RARE they're buying SG Americas Securities LLC established a new position in Ultragenyx by purchasing 125,429 shares in Q3, worth about $3.77 million and representing roughly 0.13% of the company.
0 · Reply
OptionRunners
OptionRunners Jan. 12 at 7:52 PM
$RARE bull risk reversals
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 7:19 PM
$RARE 3 quarters of a billion is cash is insane 4 approved rev stream Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 7:16 PM
$RARE all is well
0 · Reply
Zero11
Zero11 Jan. 12 at 6:38 PM
$RARE $MREO upppp
2 · Reply
Masonsy
Masonsy Jan. 12 at 6:18 PM
$RARE regarding ca$H runway, CEO should clarify $735M on hand exists 2025, cost and expenses reduction offset by new launches prep => into mid 2027 without dilution, + emphasis on profitability in 2027.
1 · Reply
NoOriginality
NoOriginality Jan. 12 at 6:17 PM
$SRPT Roll that biotech money into $RARE
0 · Reply
NoOriginality
NoOriginality Jan. 12 at 6:14 PM
$RARE Breaking $25 shortly.
0 · Reply
Masonsy
Masonsy Jan. 12 at 6:13 PM
$RARE let’s wait for CEO’s clarification on UX111 resubmission - what I heard is no later than Feb 28th. 6 month review period for FDA with PDUFA date set for Aug -Sep 2026.
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 5:55 PM
$RARE lets go!!
0 · Reply
Zezo88
Zezo88 Jan. 12 at 5:51 PM
$RARE
0 · Reply
Redsworld90
Redsworld90 Jan. 12 at 4:37 PM
$MREO $RARE slide for today.
1 · Reply
WarrenPsnik
WarrenPsnik Jan. 12 at 3:55 PM
$RARE When my covered calls expire by the eow, will have positioned myself well into recovery, which should be coming based on projected growth.
0 · Reply
roaringcharts
roaringcharts Jan. 12 at 3:07 PM
$RARE conference news will be watching
0 · Reply
Masonsy
Masonsy Jan. 12 at 2:25 PM
$RARE looks like the company doesn’t want to fully give up UX143, there may be some salvage value or even potential approval (+ after market confirmation) reflecting positive BMD, pediatric unmet needs, etc. I think the reasonable path is: no cash spending on it until strong suggestions from FDA. The company should prepare several cost reduction plans.
0 · Reply
JFais
JFais Jan. 12 at 2:03 PM
$RARE, $MREO (no position in either) "Results from Orbit & Cosmic studies in osteogenesis imperfecta, including data on bone mineral density, vertebral fractures and patient reported outcomes on pain and physical function, will be presented at JPM" Trying for totality of data?
0 · Reply
bizness1957
bizness1957 Jan. 12 at 1:26 PM
$RARE trading at 2x revs including cash so undervalued
0 · Reply